Loading…
← CockpitCompetitor Analysis › 603229.SS Zhejiang Ausun Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Ausun Pharmaceutical Co., Ltd. Class A603229.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang manufacturer of active pharmaceutical ingredients, mainly cardiovascular and anti-infective APIs, sold to generic drugmakers.

≈ A small Chinese cardiovascular-API supplierMomentum weak 29
Mkt cap
$824M
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$4.96M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥6.62
1D-1.3%
1W-5.4%
1M-13.3%
3M-21.2%
6M-34.1%
YTD-33.3%
1Y-33.9%
ATR %3.3%
52w lowhigh38.8% off high

What Zhejiang Ausun Pharmaceutical does

Zhejiang manufacturer of active pharmaceutical ingredients, mainly cardiovascular and anti-infective APIs, sold to generic drugmakers.

In one line: A small Chinese cardiovascular-API supplier.

Products and services

  • Cardiovascular APIs
  • Anti-infective APIs
  • Finished formulations

Customers

  • Generic-drug formulators worldwide

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Cardiovascular and anti-infective APIs

What could go right

  • Global generic-drug API demand

What could go wrong

  • API price competition
  • Environmental compliance costs

Moat: none (scale). Commodity API producer competing mainly on cost and regulatory filings.

Headquarters: Taizhou, Zhejiang, China · Employees: 1,328

Named competitors

Zhejiang Ausun Pharmaceutical at a glance

Size Zhejiang Ausun Pharmaceutical (603229.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $824M, the 2526th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.62 on 18 Nov 2026.

Performance Over six months the shares fell 34.1%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue grew 1.0% over the last twelve months (peer median +7.7%); the operating margin is 0.2% (peer median 10.0%).

Valuation It trades at 6.5× enterprise value to sales against a peer median of 2.9× (5th most expensive of 17).

Capital Return on invested capital runs 2.3 points below its cost of capital (5.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 91603229.SS 66
Six months, rebased to 100: Zhejiang Ausun Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Ausun Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥757MCN¥787MCN¥790MCN¥814MCN¥763M
Revenue growth—0%-3%+7%—
Gross profitCN¥406MCN¥399MCN¥414MCN¥435MCN¥380M
EBITDAn/aCN¥187MCN¥243MCN¥282MCN¥238M
Net income-CN¥4.53MCN¥131MCN¥207MCN¥254MCN¥235M
Free cash flow-CN¥50.4MCN¥52.1MCN¥66.6MCN¥58.4M-CN¥151M
Capital expenditureCN¥96.4MCN¥104MCN¥111MCN¥163MCN¥272M
Total debtCN¥407MCN¥540MCN¥416MCN¥413MCN¥391M

Quarterly statements and history in the cockpit →

Zhejiang Ausun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-50%-25%0%+25%0008130020823002676078COLLSUVEN688073688621RIGLSANOFI688176ORIC086450069620GUDIRWDCRVS603229.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Ausun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×250×500×750×0008130020823002676078COLLSUVEN688176GUDIRWD603229.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Ausun Pharmaceutical is the large dot.

Zhejiang Ausun Pharmaceutical competitors and peer comparison

Head to head with its named competitors (603229.SS vs 002099.SZ vs 600521.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Zhejiang Ausun Pharmaceutical 603229.SS$824M-34%+1%0%6.5×n/a
Zhejiang Hisoar Pharmaceutical 002099.SZ$1.33B-2%+9%-13%4.7×n/a
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%3.2×6.4%

How Zhejiang Ausun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Ausun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603229.SSPeer medianRank in peer set
1-month return-13.3%-7.0%7th lowest of 20
6-month return-34.1%-7.9%3rd lowest of 19
Distance from 52-week high-38.8%-34.1%9th lowest of 20
Revenue growth (TTM)+1.0%+7.7%6th lowest of 18
Operating margin0.2%10.0%8th lowest of 18
EV / Sales6.5×2.9×5th most expensive of 17
ROIC minus cost of capital-2.3 pp-0.7 pp8th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a

Questions

Who are Zhejiang Ausun Pharmaceutical's main competitors?
Named competitors: Zhejiang Hisoar Pharmaceutical (002099.SZ), Zhejiang Huahai Pharmaceutical (600521.SS). The cockpit's measured peer set (industry) also includes Dezhan Healthcare (000813.SZ), Wanbangde Pharmaceutical (002082.SZ), Hunan Er-Kang Pharmaceutical (300267.SZ), Hygeia Healthcare (6078.HK), Collegium Pharmaceutical (COLL), Suven Life Sciences (SUVEN.NS).
Is Zhejiang Ausun Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 6.5× against a peer median of 2.9×, 5th most expensive of 17 in its peer set.
How has Zhejiang Ausun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -34.1% against -7.9% for the median peer; over one year -33.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.